Resumo

BARRAGAN CARRILLO, Regina et al. Contemporary treatment of advanced renal cancer: from surveillance to immunotherapy. Acta méd. Grupo Ángeles [online]. 2022, vol.20, n.4, pp.342-346.  Epub 26-Maio-2023. ISSN 1870-7203.  https://doi.org/10.35366/107119.

Clear cell renal carcinoma (CCRC) represents 3% of worldwide overall cancer cases. 14.5% of patients in Latin America are diagnosis with de novo metastatic disease, and about 30% of localized cases present a systemic recurrence. The International Metastatic CCRC Database Consortium classifies patients according to favorable, intermediate, and poor prognosis at the time of diagnosis. Given the biological variability of the disease, treatment strategies go from active surveillance to systemic therapy with immunotherapy-based combinations. In this review, we highlight the criteria to consider in the selection of treatment in advanced CCRC. Furthermore, we highlight recent data arising from clinical trials that led to changes in the treatment paradigm.

Palavras-chave : Renal cancer; immunotherapy; white therapy; anti-PD-1; anti-CTLA-4.